Congress Eyes Generic Biotech Drugs
The move, which could have a large impact on the pharmaceutical industry, comes after years of officials and insurers clamoring for change. Currently, there is no statutory pathway for lower price biotech drugs, even after patents expire.
This fall Sen. Hillary Clinton (D-N.Y.) and Sen. Charles Schumer (D-N.Y.) with Rep. Henry Waxman (D-Calif.) proposed the Access...
To view the full article, register now.